专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2014073845A1 A COMPOSITION FOR TREATING DIABETES OR DIABESITY COMPRISING OXYNTOMODULIN ANALOG 审中-公开
标题翻译：用于治疗包含氧自由基蛋白类似物的糖尿病或脂蛋白的组合物
公开(公告)号：WO2014073845A1
公开(公告)日：2014-05-15
申请号：PCT/KR2013/009990
申请日：2013-11-06
申请人： HANMI PHARM. CO., LTD.
发明人： KIM, Jin Sun , KIM, Dae Jin , LEE, Sang Hyun , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： A61K38/26 , C07K14/605 , A61K39/395 , A61P3/10
CPC分类号： C07K14/575 , A61K38/22 , A61K47/643 , A61K47/6435 , C07K14/605 , C07K16/00 , C07K16/3046 , C07K2319/30 , C07K2319/31
摘要： The present invention relates to a composition for preventing or treating diabetes, disbesity or diabetic complications, comprising an oxyntomodulin analog as an active ingredient. The invention also relates to a method for treating diabetes, diabesity or diabetic complications, comprising administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog has a high ability to activate the GLP-1 receptor and the glucagon receptor, compared to native oxyntomodulin. The oxyntomodulin analog induces the expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in body weight and diet intake to improve insulin sensitivity and allow blood glucose levels, which are not controlled due to insulin resistance, to be maintained at normal levels. Thus, the oxyntomodulin analog can be effectively used to prevent or treat of diabetes and related diseases.
摘要翻译：本发明涉及用于预防或治疗糖尿病，消瘦或糖尿病并发症的组合物，其包含胃泌酸调节素类似物作为活性成分。本发明还涉及一种治疗糖尿病，肥胖症或糖尿病并发症的方法，包括向受试者施用药学有效量的胃泌酸调节素类似物。与天然胃泌酸调节素相比，胃泌酸调节蛋白类似物具有高的活化GLP-1受体和胰高血糖素受体的能力。胃泌酸调节蛋白类似物诱导β-细胞的扩增并增加胰岛素分泌，从而降低由于高热量和高脂肪饮食而增加的血糖水平。胃泌酸调节蛋白类似物诱导体重和饮食摄取量的降低以改善胰岛素敏感性并且使由胰岛素抵抗引起的不受控制的血糖水平维持在正常水平。因此，胃泌酸调节蛋白类似物可以有效地用于预防或治疗糖尿病和相关疾病。

52. 发明申请

WO2014017845A3 A LIQUID FORMULATION OF LONG ACTING INSULINOTROPIC PEPTIDE CONJUGATE 审中-公开
标题翻译：长效胰岛素肽共轭物的液体制剂
公开(公告)号：WO2014017845A3
公开(公告)日：2014-01-30
申请号：PCT/KR2013/006670
申请日：2013-07-25
申请人： HANMI PHARM. CO., LTD.
发明人： KIM, Hyun Uk , LIM, Hyung Kyu , HONG, Sung Hee , KIM, Dae Jin , BAE, Sung Min , KWON, Se Chang
IPC分类号： A61K9/08 , A61K38/26 , A61K38/28 , A61K47/48
摘要： The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.
摘要翻译：本发明涉及长效促胰岛素肽缀合物的液体制剂，其包含药学有效量的由生理活性肽，促胰岛素肽和免疫球蛋白Fc组成的长效促胰岛素肽缀合物地区; 和不含白蛋白的稳定剂，其中稳定剂包含缓冲剂，糖醇，非离子表面活性剂和等渗剂，以及制备该制剂的方法。为了防止微生物污染，可以加入防腐剂。本发明的液体制剂不含人血清白蛋白和其它对身体有潜在危害的因素，没有病毒污染的风险，因此可以为高浓度的促胰岛素肽缀合物提供优异的储存稳定性。

53. 发明申请

WO2013157792A1 BICYCLIC HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 审中-公开
标题翻译：双相异构体衍生物和药物组合物
公开(公告)号：WO2013157792A1
公开(公告)日：2013-10-24
申请号：PCT/KR2013/003149
申请日：2013-04-15
申请人： HANMI PHARM. CO., LTD.
发明人： JUNG, Seung Hyun , KIM, Ji Sook , HONG, Dong Jin , JUNG, Young Hee , JANG, Wook
IPC分类号： C07D495/04 , A61K31/519 , A61P3/00 , A61P9/00
CPC分类号： C07D495/04 , C07D519/00
摘要： Bicyclic heteroaryl derivatives of Formula 1, and pharmaceutically acceptable salts, isomers, hydrates and solvates thereof can selectively and effectively inhibit DGAT1, and thus can be useful as medicines for effectively treating dangerous diseases such as obesity, type 2 diabetes, abnormal lipidemia, metabolic syndrome (syndrome X) and the like, which are caused by DGAT1, with no adverse side effects.
摘要翻译：式1的双环杂芳基衍生物及其药学上可接受的盐，异构体，水合物和溶剂化物可以选择性和有效地抑制DGAT1，因此可用作有效治疗诸如肥胖，2型糖尿病，异常脂血症，代谢综合征等危险疾病的药物（综合征X）等，其由DGAT1引起，没有不良副作用。

54. 发明申请

WO2013154390A1 COMPOSITE FORMULATION COMPRISING MULTI-UNIT SPHEROIDAL TABLET (MUST) ENCAPSULATED IN HARD CAPSULE AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：包含硬化胶囊中的多单位片剂（必须）的复合制剂及其制备方法
公开(公告)号：WO2013154390A1
公开(公告)日：2013-10-17
申请号：PCT/KR2013/003099
申请日：2013-04-12
申请人： HANMI PHARM. CO., LTD.
发明人： KIM, Kyeong Soo , KIM, Dong Ho , KWON, Taek Kwan , KIM, Yong Il , PARK, Jae Hyun , WOO, Jong Soo
IPC分类号： A61K9/48 , A61K9/52 , A61K9/28 , A61K47/30
CPC分类号： A61K9/4808 , A61K9/4833 , A61K9/4891 , A61K31/137 , A61K31/4178 , A61K31/4365 , A61K31/4422 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/505 , A61K31/616 , A61K2300/00
摘要： Provided is a composite formulation comprising multi-unit spheroidal tablets (MUSTs) encapsulated in a hard capsule and a method for preparing same. The inventive hard capsule composite formulation can effectively charge the MUSTs in the limited space of the capsule, which allows charging a high dose of different pharmaceutically active ingredients in a capsule with a relatively small size, to thereby increase the productivity and render it readily administered to patients. Also, the capsule has a good dissolution rate because the pharmaceutically active ingredients contained in the capsule are separated from one another; therefore, the dissolution rates of the ingredients are less affected by one another. It may also be possible to maximize the therapeutic effects of the pharmaceutically active ingredients since the composite formulation has good stability.
摘要翻译：本发明提供了包含在硬胶囊中的多单位球形片剂（MUSTs）的复合制剂及其制备方法。本发明的硬胶囊复合制剂可以有效地对胶囊的有限空间中的MUST进行充电，这允许在相对较小尺寸的胶囊中装入高剂量的不同药物活性成分，从而提高生产率并使其容易地施用于耐心。此外，胶囊具有良好的溶解速度，因为包含在胶囊中的药物活性成分彼此分离; 因此，成分的溶解速度较少受到彼此的影响。由于复合制剂具有良好的稳定性，也可能使药物活性成分的治疗效果最大化。

55. 发明申请

WO2013154347A1 LIQUID FORMULATION FOR ORAL ADMINISTRATION COMPRISING AMBROXOL, LEVODROPROPIZINE AND BUFFERING AGENT, AND METHOD FOR PREPARING THE SAME 审中-公开
标题翻译：用于包含阿莫罗醇，屈葛酸和缓冲剂的口服给药的液体制剂及其制备方法
公开(公告)号：WO2013154347A1
公开(公告)日：2013-10-17
申请号：PCT/KR2013/002999
申请日：2013-04-10
申请人： HANMI PHARM. CO., LTD.
发明人： KIM, Yong Il , KIM, Jin Cheul , KIM, Jae Ho , KIM, Yo Han , PARK, Jae Hyun , WOO, Jong Soo
IPC分类号： A61K9/08 , A61K31/136 , A61K31/135
CPC分类号： A61K9/08 , A61K31/137 , A61K31/495 , A61K47/10 , A61K47/14 , A61K47/20 , A61K47/26 , A61K2300/00
摘要： A liquid formulation for oral administration comprising ambroxol, levodropropizine and a buffering agent, and a method for preparing such formulation are provided. This liquid formulation shows enhanced storage stability over time and improved patient compliance, and thus can be safely used for the treatment of acute and chronic cough.
摘要翻译：提供了包含氨溴索，左旋佛波胺和缓冲剂的口服液体制剂及其制备方法。该液体制剂随时间显示增强的储存稳定性和改善的患者依从性，因此可以安全地用于治疗急性和慢性咳嗽。

56. 发明申请

WO2013100630A1 FIXED DOSE COMBINATION FORMULATION COMPRISING LOSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE 审中-公开
标题翻译：含有洛沙坦，阿莫西汀和氢氯酸的固定剂量组合配方
公开(公告)号：WO2013100630A1
公开(公告)日：2013-07-04
申请号：PCT/KR2012/011569
申请日：2012-12-27
申请人： HANMI PHARM. CO., LTD.
发明人： KIM, Yong Il , KIM, Kyeong Soo , PARK, Seung Jae , PARK, Jae Hyun , WOO, Jong Soo
IPC分类号： A61K9/48 , A61K31/417 , A61K31/44 , A61P9/00
CPC分类号： A61K9/5084 , A61K9/2072 , A61K9/4808 , A61K31/4178 , A61K31/4422 , A61K31/549 , A61K2300/00
摘要： Provided is a fixed dose combination formulation for the prophylaxis or therapy of cardiovascular diseases, comprising losartan, amlodipine and hydrochlorothiazide, which is superior in dissolution rate and stability, having a higher dissolution rate compared to conventional individual single or combined dosage forms, the fixed dose combination formulation of the present invention exhibits biologically equivalent or superior behaviors to the conventional forms and guarantees higher stability over time. Therefore, the fixed dose combination formulation of the present invention can be effectively applied to the prophylaxis or therapy of cardiovascular diseases.
摘要翻译：提供了用于预防或治疗心血管疾病的固定剂量组合制剂，其包含氯沙坦，氨氯地平和氢氯噻嗪，其溶解速率和稳定性优异，与常规单独的单一或组合剂型相比具有较高的溶解速率，固定剂量本发明的组合制剂表现出与常规形式的生物等效或优异的行为，并保证随时间的更高的稳定性。因此，本发明的固定剂量组合制剂可以有效地应用于预防或治疗心血管疾病。

57. 发明申请

WO2013012199A1 CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE 审中-公开
标题翻译：包含MONTELUKAST和LEVOCETIRIZINE的胶囊制剂
公开(公告)号：WO2013012199A1
公开(公告)日：2013-01-24
申请号：PCT/KR2012/005506
申请日：2012-07-11
申请人： HANMI PHARM. CO., LTD. , KIM, Yong Il , KIM, Dong Ho , KWON, Taek Kwan , KIM, Kyeong Soo , PARK, Jae Hyun , WOO, Jong Soo
发明人： KIM, Yong Il , KIM, Dong Ho , KWON, Taek Kwan , KIM, Kyeong Soo , PARK, Jae Hyun , WOO, Jong Soo
IPC分类号： A61K9/48 , A61K31/47 , A61K31/4704 , C07D215/18
CPC分类号： A61K9/4808 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/4816 , A61K31/47 , A61K31/473 , A61K31/495 , A61K31/4965 , C07D215/12 , C07D295/06 , C07D295/08 , A61K2300/00
摘要： Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.
摘要翻译：公开了一种用于预防或治疗过敏性鼻炎和哮喘的胶囊制剂，其包含两个单独的层：（1）包含孟鲁司特或其药学上可接受的盐的蒙特卡斯特层; 和（2）包含左西替利嗪或其药学上可接受的盐的左西替利嗪层; 及其制备方法。根据本发明的胶囊制剂可以完全分离两种活性成分，从而最小化它们之间的反应性并提高产品对抗老化作用的稳定性，从而可以优化治疗效果。

58. 发明申请

WO2010107256A2 METHOD FOR PREPARING A SITE-SPECIFIC PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE 审中-公开
标题翻译：制备特异性生理活性多肽的方法
公开(公告)号：WO2010107256A2
公开(公告)日：2010-09-23
申请号：PCT/KR2010/001674
申请日：2010-03-18
申请人： HANMI PHARM. CO., LTD. , SONG, Dae Hae , SHIN, Jae Hee , LEE, Jae Min , PARK, Young Kyung , KWON, Se Chang , LEE, Gwan Sun
发明人： SONG, Dae Hae , SHIN, Jae Hee , LEE, Jae Min , PARK, Young Kyung , KWON, Se Chang , LEE, Gwan Sun
IPC分类号： C07K1/14 , C07K1/10 , C07K1/18
CPC分类号： C07K1/1077 , A61K47/60 , C07K14/575 , C07K14/605 , C07K14/62
摘要： The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.
摘要翻译：本发明提供了一种通过在特定pH下在醇的存在下用非肽基聚合物处理生理活性多肽而以高产率制备位点特异性生理活性多肽缀合物的方法，其可以理想地用于开发具有高体内活性和明显延长的血液半衰期的各种肽药物的长效制剂。

59. 发明申请

WO2010085027A1 SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN WITH IMPROVED STABILITY 审中-公开
标题翻译：包含具有改善稳定性的阿片和洛沙坦的固体药物组合物
公开(公告)号：WO2010085027A1
公开(公告)日：2010-07-29
申请号：PCT/KR2009/003028
申请日：2009-06-05
申请人： HANMI PHARM. CO., LTD. , PARK, Jae Hyun , KIM, Kyeong Soo , YIM, Ho Taek , IM, Ji Hyun
发明人： PARK, Jae Hyun , KIM, Kyeong Soo , YIM, Ho Taek , IM, Ji Hyun
IPC分类号： A61K9/16 , A61P9/12 , A61P25/28 , A61K31/44 , A61K31/4178
CPC分类号： A61K31/41 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/5084 , A61K31/4178 , A61K31/44 , A61K31/4422 , A61K2300/00
摘要： The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent, which has improved storage stability due to minimized interaction between amlodipine and losartan.
摘要翻译：本发明涉及用于预防或治疗心血管疾病的固体药物组合物，其包含彼此分离的氨氯地平和氯沙坦的颗粒形式，以及由于氨氯地平与氯沙坦之间的相互作用最小化而具有改善的储存稳定性的稳定剂。

60. 发明申请

WO2010085014A1 SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN AND PROCESS FOR PRODUCING SAME 审中-公开
标题翻译：包含AMLODIPINE和LOSARTAN的固体药物组合物及其生产方法
公开(公告)号：WO2010085014A1
公开(公告)日：2010-07-29
申请号：PCT/KR2009/000704
申请日：2009-02-13
申请人： HANMI PHARM. CO., LTD. , PARK, Jae Hyun , KIM, Kyeong Soo , YIM, Ho Taek
发明人： PARK, Jae Hyun , KIM, Kyeong Soo , YIM, Ho Taek
IPC分类号： A61K31/44
CPC分类号： A61K31/41 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/5084 , A61K31/4178 , A61K31/44 , A61K31/4422 , A61K2300/00
摘要： The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof, which exhibits high dissolution rates of amlodipine and losartan even under a low pH condition and improved storage stability.
摘要翻译：本发明涉及用于预防或治疗心血管疾病的固体药物组合物，其包括氨氯地平或其药学上可接受的盐和氯沙坦或其药学上可接受的盐，其甚至在低pH条件下也显示出高的氨氯地平和氯沙坦溶解速率，并且改善了储存稳定性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式